Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Holding NVCT?
Track your performance easily
NVCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.52 - $12.10
Previous Close$4.7
Volume95.53K
Average Volume (3M)171.87K
Market Cap
$90.81M
Enterprise Value$73.61M
Total Cash (Recent Filing)$17.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Mar 11, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding19,320,973
10 Day Avg. Volume77,215
30 Day Avg. Volume171,873
Standard Deviation0.20
R-Squared0.00241
Alpha0.00735
Financial Highlights & Ratios
Price to Book (P/B)8.25
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.06
Enterprise Value/Ebitda-3.71
Forecast
1Y Price Target
$20.50Price Target Upside320.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Nuvectis Pharma News
PremiumCompany Announcements
Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress
Ownership Overview
34.15% Insiders
1.89% Mutual Funds
1.66% Other Institutional Investors
60.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $4.52 and its highest was $12.10 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Currently, no data Available
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Mar 11, 2025 which is in 79 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Nov 05, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.012.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -$0.25.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 19,320,972 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went up 17.75%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
---
Nuvectis Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.50 (320.94% Upside)
$20.50 (320.94% Upside)
Insider Transactions
Bought Shares
Worth $165.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.57%
12-Months-Change
Fundamentals
Return on Equity
-140.00%
Trailing 12-Months
Asset Growth
-22.26%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
---
NVCT Stock 12 Month Forecast
Average Price Target
$20.50
▲(320.94% Upside)
Technical Analysis
Alaunos Therapeutics
―
Forte Biosciences
―
180 Life Sciences
―
Virax Biolabs Group Ltd. Class A
―
Best Analysts Covering NVCT
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-33.56%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -33.56% per trade.
---